drugset
drugset / Trial / NCT01623869

Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery

NCT01623869 ↗

Phase 2 Completed 16 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well trebananib works in treating patients with advanced angiosarcoma that cannot be removed by surgery. Trebananib may stop the growth of tumor cells by blocking blood flow to the tumor.

Timeline

Start
2012-07
Primary completion
2014-09
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Trebananib Peptide 30 mg/kg Intravenous

Indications

angiosarcoma